TY - JOUR
T1 - A human STAT3 gain-of-function variant confers T cell dysregulation without predominant Treg dysfunction in mice
AU - Schmitt, Erica G.
AU - Toth, Kelsey A.
AU - Risma, Samuel I.
AU - Kolicheski, Ana
AU - Saucier, Nermina
AU - Feliciano Berríos, Rafael J.
AU - Greenberg, Zev J.
AU - Leiding, Jennifer W.
AU - Bleesing, Jack J.
AU - Thatayatikom, Akaluck
AU - Schuettpelz, Laura G.
AU - Edwards, John R.
AU - Vogel, Tiphanie P.
AU - Cooper, Megan A.
N1 - Funding Information:
We would like to thank Kelsey Trammel and Molly Keppel for technical assistance. We thank the Genome Technology Access Center at the McDonnell Genome Institute at Washington University School of Medicine for help with genomic analysis. The Center is partially supported by NCI Cancer Center Support Grant no. CA P30CA091842 to the Siteman Cancer Center from the National Center for Research Resources (NCRR), a component of the NIH, and NIH Roadmap for Medical Research. This publication is solely the responsibility of the authors and does not necessarily represent the official view of NCRR or NIH. This work was supported by the Hope Center Transgenic Vectors Core at Washington University School of Medicine. Michael Wallendorf provided biostatistical support for the murine colitis studies. EGS was supported by NIH grants K12HD076224, T32HD043010, and T32AI106688 and a Washington University Rheumatic Diseases Research Resource-based Center (RDRRC) Pilot and Feasibility Grant (NIH P30AR073752). Grant support was received from NIH/NIAID 1P01AI155393, the National Scleroderma Foundation, the Crohn’s and Colitis Foundation, the Washington University Digestive Disease Research Core Center (NIH 5P30DK052574), the RDRRC NIH P30AR48335, and the Children’s Discovery Institute at St. Louis Children’s Hospital and Washington University (to MAC).
Funding Information:
EGS was supported by NIH grants K12HD076224, T32HD043010, and T32AI106688 and a Washington University Rheumatic Diseases Research Resource-based Center (RDRRC) Pilot and Feasibility Grant (NIH P30AR073752). Grant support was received from NIH/NIAID 1P01AI155393, the National Scleroderma Foundation, the Crohn’s and Colitis Foundation, the Washington University Digestive Disease Research Core Center (NIH 5P30DK052574), the RDRRC NIH P30AR48335, and the Children’s Discovery Institute at St. Louis Children’s Hospital and Washington University (to MAC).
Funding Information:
We would like to thank Kelsey Trammel and Molly Keppel for technical assistance. We thank the Genome Technology Access Center at the McDonnell Genome Institute at Washington University School of Medicine for help with genomic analysis. The Center is partially supported by NCI Cancer Center Support Grant no. CA P30CA091842 to the Siteman Cancer Center from the National Center for Research Resources (NCRR), a component of the NIH, and NIH Roadmap for Medical Research. This publication is solely the responsibility of the authors and does not necessarily represent the official view of NCRR or NIH. This work was supported by the Hope Center Transgenic Vectors Core at Washington University School of Medicine. Michael Wallendorf provided biostatistical support for the murine colitis studies.
Publisher Copyright:
© 2022, Schmitt et al.
PY - 2022/11/8
Y1 - 2022/11/8
N2 - Primary immune regulatory disorders (PIRD) represent a group of disorders characterized by immune dysregulation, presenting with a wide range of clinical disease, including autoimmunity, autoinflammation, or lymphoproliferation. Autosomal dominant germline gain-of-function (GOF) variants in STAT3 result in a PIRD with a broad clinical spectrum. Studies in patients have documented a decreased frequency of FOXP3+ Tregs and an increased frequency of Th17 cells in some patients with active disease. However, the mechanisms of disease pathogenesis in STAT3 GOF syndrome remain largely unknown, and treatment is challenging. We developed a knock-in mouse model harboring a de novo pathogenic human STAT3 variant (p.G421R) and found these mice developed T cell dysregulation, lymphoproliferation, and CD4+ Th1 cell skewing. Surprisingly, Treg numbers, phenotype, and function remained largely intact; however, mice had a selective deficiency in the generation of iTregs. In parallel, we performed single-cell RNA-Seq on T cells from STAT3 GOF patients. We demonstrate only minor changes in the Treg transcriptional signature and an expanded, effector CD8+ T cell population. Together, these findings suggest that Tregs are not the primary driver of disease and highlight the importance of preclinical models in the study of disease mechanisms in rare PIRD.
AB - Primary immune regulatory disorders (PIRD) represent a group of disorders characterized by immune dysregulation, presenting with a wide range of clinical disease, including autoimmunity, autoinflammation, or lymphoproliferation. Autosomal dominant germline gain-of-function (GOF) variants in STAT3 result in a PIRD with a broad clinical spectrum. Studies in patients have documented a decreased frequency of FOXP3+ Tregs and an increased frequency of Th17 cells in some patients with active disease. However, the mechanisms of disease pathogenesis in STAT3 GOF syndrome remain largely unknown, and treatment is challenging. We developed a knock-in mouse model harboring a de novo pathogenic human STAT3 variant (p.G421R) and found these mice developed T cell dysregulation, lymphoproliferation, and CD4+ Th1 cell skewing. Surprisingly, Treg numbers, phenotype, and function remained largely intact; however, mice had a selective deficiency in the generation of iTregs. In parallel, we performed single-cell RNA-Seq on T cells from STAT3 GOF patients. We demonstrate only minor changes in the Treg transcriptional signature and an expanded, effector CD8+ T cell population. Together, these findings suggest that Tregs are not the primary driver of disease and highlight the importance of preclinical models in the study of disease mechanisms in rare PIRD.
UR - http://www.scopus.com/inward/record.url?scp=85141892052&partnerID=8YFLogxK
U2 - 10.1172/jci.insight.162695
DO - 10.1172/jci.insight.162695
M3 - Article
C2 - 36136607
AN - SCOPUS:85141892052
SN - 2379-3708
VL - 7
JO - JCI insight
JF - JCI insight
IS - 21
M1 - e162695
ER -